Happy to share my thesis work, now online at bioRxiv. We show that LDB1 organizes Enhancer-Promoter interaction networks and can function independently of cohesin! biorxiv.org/content/10.110…

Tremendously proud to share my fellowship work, online today in Nature Medicine. We tried to understand why CAR T therapy for AML doesn't work as well as we hoped it would, and how we can solve that. 👇🧵1/10 Penn Medicine CHOP Research Saar Gill nature.com/articles/s4159…

Looking forward to discussing our latest work on CD5 next week! Register here to join: workcast.com/register?cpak=…

Learn more about the exciting advances in blood cancer and benign hematology research that Penn Medicine and Penn Medicine - Abramson Cancer Center experts will be presenting at the ASH Annual Meeting this weekend. #ASH24 spr.ly/6015txypB

#ASH24 Energy matters! Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate #CARTCell #TCell #tcellrx #immunotherapy Penn Medicine ash.confex.com/ash/2024/webpr…

Grateful to #ASH2024 for the chance to present our work on overcoming the absence of CD2:CD58 co-stimulation using an innovative PD1:iCD2 switch receptor. Thanks to my mentor Marco Ruella and the Ruella Lab for their invaluable support. Excited to delve deeper into this approach!

A simple dietary supplement may provide a new approach to boost #CART cell function – hear more in the #ASH24 Plenary Session today. Marco Ruella Maayan Levy Puneeth Guruprasad spr.ly/6015QKswz

Huge honor to present our work on enhancing CAR T cell function via dietary intervention in the Plenary Session at #ASH2024!Grateful for the chance! Special thanks to the co-leader Puneeth Guruprasad and to our mentors @MaayanLevy_Lab and Marco Ruella for their support💜Penn Medicine

Wild experience to have seen our story shared at the #ASH24 Plenary in San Diego by my wonderful co-lead Shan Liu ! Looking forward to further proving that we can enhance cancer treatment by modulating readily-actionable patient lifestyle factors.

cell.com/molecular-cell… Our paper is now online Molecular Cell. Architectural protein LDB1 drives enhancer connectivity independently of CTCF/cohesin!

Thrilled to share our new paper in Nature Medicine! We analyzed 783 patients (2,200+ patient-years) receiving lentiviral or gammaretroviral T cell therapies and found no evidence of high-level insertional mutagenesis. nature.com/articles/s4159…

CAR T cells have shown efficacy in blood cancers and autoimmune disease. In my lab’s recent preprint, we developed CAR Tregs to tackle the #1 cause of human mortality - heart disease. biorxiv.org/content/10.110…

Gutting the NIH will kill Americans: - Patients lose access to lifesaving medicine - 1000s of lost jobs at NIH and across academia - No research funding = no new medicines and treatments - Fewer trainees/medicines = pharma + health sector crash These are only a few. Buckle up.

Congrats Patrizia Porazzi and star undergrad Siena Nason (who is going to kill it during her PhD)!

Exciting news: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models Cancer Cell Marco Ruella Alberto Carturan Puneeth Guruprasad Ruchi Patel Yunlin Zhang Guido Ghilardi and my stellar co-author Siena Nason cell.com/cancer-cell/ab…

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,

Is it guaranteed that pushing this work forward would make a huge impact? Of course not! But a healthy research ecosystem must place smart bets on scientists with crazy, commercially uncertain ideas, because a few of those bets might end up pushing us all forward

More than 60% of cancer patients undergo surgery as a part of their treatment plan, and relapse often stems from minimal residual disease (MRD). In 2024, Peter Marks highlighted elimination of MRD as low-hanging fruit for CAR T cells.